ELVN - Company ID 0001672619
The table below shows Enliven Therapeutics, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $98.90M | $124.12M | $100.14M | $88.20M | $48.31M | $47.70M |
| Short-term investments | $363.73M | $189.32M | $153.01M | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $474.88M |
| $318.13M |
| $266.15M |
| $89.64M |
| $92.70M |
| $90.41M |
| Property, plant & equipment | $34.00K | $458.00K | $742.00K | $250.00K | $250.00K | $349.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $476.17M | $325.76M | $271.87M | $91.96M | $93.65M | $90.84M |
| Accounts payable | $2.16M | $1.34M | $532.00K | $149.00K | $2.36M | $1.97M |
| Total current liabilities | $16.57M | $15.91M | $25.89M | $1.83M | $7.21M | $6.25M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $16.57M | $15.91M | $25.96M | $1.83M | $7.62M | $6.41M |
| Retained earnings | -$347.17M | -$243.47M | -$154.45M | -$146.01M | -$147.50M | -$96.11M |
| Total equity | $459.60M | $309.85M | $245.91M | $90.13M | $86.03M | $84.44M |